Physician profile
Malik Khan
NPI 1740539733
$1,898.46
in general payments reported to CMS, 2019-2025
14 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.45 · 2022: $685 · 2023: $213 · 2024: $398 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $100 · Education: $80.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100.00 |
| Education | $80.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $500.00 | 2022 | |
| Genzyme Corporation | $365.48 | 2021-2025 | |
| Verona Pharma, INC. | $178.05 | 2025 | Ohtuvayre |
| Inari Medical, INC. | $133.76 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Mylan Specialty L.P. | $129.73 | 2022-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $124.23 | 2025 | Dupixent |
| Amgen INC. | $119.91 | 2024 | Tavneos |
| Eko Health, INC. | $100.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.15 | 2023-2025 | Glassia |
| Glaxosmithkline, LLC. | $84.04 | 2023-2025 | Nucala, Trelegy Ellipta |
| Abiomed | $61.20 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $12.91 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malik Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.